Frost & Sullivan Hosts Free Webinar: Impact of the Patient Protection and Affordable Care Act (PPACA): What Does it Mean for Healthcare Technology and Pharmaceutical Companies?

MOUNTAIN VIEW, Calif., June 24 /PRNewswire/ --

(Logo:  http://photos.prnewswire.com/prnh/20081117/FSLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The Provisions of the Patient Protection and Affordable Care Act (PPACA) signed on March 23, 2010 will be rolled out through 2014 with significant impact on the U.S. healthcare system. The expansion of healthcare insurance coverage expects to create a large pool of patients and more demand for healthcare technologies, goods and services. But the impact of Medicare cuts, comparative effectiveness research (CER) initiatives, wellness programs, healthcare insurance exchanges and other components of the legislation are less clear. What does this Act mean for pharmaceutical/ biotech, medical device and diagnostics, and healthcare information technology companies, and others serving the U.S. healthcare sector?

Frost & Sullivan will assemble a multi-disciplinary team of its top analysts and consultants tracking this issue to discuss the most important implications of the Act. Major provisions of the Act and the expected impact on specific markets will be presented. Findings of a recent Frost & Sullivan survey of 90 medical device industry professionals regarding the anticipated impact of the Act on the market, as well as conclusions from a large focus group of hospital CIOs, will be integrated into the presentation.

This briefing will benefit executives responsible for strategic planning, product development and R&D at pharmaceutical/ biotech, medical device and diagnostics, and healthcare information technology companies, as well as other companies targeting the U.S. healthcare sector for future growth.  The expected short- and long-term impact of the PPACA on various markets will be discussed.

Supporting Quote

"The PPACA is the most important piece of healthcare legislation signed since Medicare in 1965," states Greg Caressi, Frost & Sullivan's Senior Vice President of Healthcare & Life Sciences.

"Its impact will be felt by every company providing any products and services to the U.S. healthcare system. With provisions to open up healthcare access to 32 million U.S. residents, cut Medicare rates, encourage the adoption of wellness programs and other actions, it will be critical for competitors in the healthcare field to carefully assess the potential opportunities and risks."

Supporting Resources

For more information about Frost & Sullivan's Healthcare practice, please visit:

http://www.healthcare.frost.com.  

Registration

• To attend the briefing, email [email protected] your full name, title, company name, company telephone number, company email address, city, state and country.
• Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

SOURCE Frost & Sullivan